Should we be screening for COPD? - looking through the lens of lung cancer screening

Expert Rev Respir Med. 2023 Sep 20. doi: 10.1080/17476348.2023.2259800. Online ahead of print.ABSTRACTINTRODUCTION: In May 2022, the US Preventive Services Task Force published their recommendation against screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults. However, we argue the routine use of spirometry in both asymptomatic and symptomatic high-risk smokers has utility.AREAS COVERED: We provide published and unpublished observations from a secondary analyses of the American College of Radiology Imaging Network(ACRIN), arm of the National Lung Screening Trial, including 18,643 high-risk current or former smokers who underwent pre-bronchodilator spirometry at baseline. According to history alone, 20% reported a prior diagnosis of 'COPD,' although only 11% (about one half), actually had airflow limitation (Diagnosed COPD) and 9% had Global Initiative for Obstructive Pulmonary Disease GOLD 0 Pre-COPD. Of the remaining 80% of 'asymptomatic' screening participants, 23% had airflow limitation (Screen-detected COPD) and 13% had preserved ratio impaired spirometry (PRISm). This means 45% of this high-risk cohort were reclassified by spirometry, and together with comorbid disease, identified subgroups where lung cancer screening efficacy could be optimized by between 2-6 fold.EXPERT OPINION: Our preliminary findings suggest lung cancer screening outcomes vary according to 'new' COPD-related spirometric-defined subgroups and that screening spirometry, tog...
Source: Expert Review of Respiratory Medicine - Category: Respiratory Medicine Authors: Source Type: research